MoleculeMind

Research on the record

• 2026-09-11MoleculeMind's QuantaMind, a learned force field for reactive molecular dynamics, appears in Science Advances: near-DFT accuracy on systems of about ten thousand atomsLevel 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-06-17Series A (extension) · A-series cumulative total over US$100 millionconfirmedWith Lanqiao Capital, Pudong Venture Capital, COFCO Emerging Industry Fund, Oriental Fortune Capital, Fosun Capital, Sepax Technologies, Guofang Capital, Infinity Group, Caixin Capital, Zhengding · Existing investors Cathay Biotech, Xinhang CapitalStated use: global industrialisation of its protein-design stack
• 2024-09-13Series A · several hundred million yuanconfirmedLed by Xienuo Investment, Shenzhen Capital Group · With SenseTime Guoxiang Capital, Jiuyi InvestmentStated use: team, protein foundation model and MoleculeOS
• 2023-02-20Pre-A · over 100 million yuanconfirmedLed by Cathay Biotech · With Lenovo Capital, Sequoia ChinaStated use: MoleculeOS development; biologics design and synthetic biology
• 2022-04-18Angel · tens of millions of US dollarsconfirmedLed by Sequoia China · With Baidu Ventures, Life Garden Venture Fund, Xinhang Capital, Weilai QichuangStated use: team, platform and productising research

Each round links to its line on the funding record, with its source.

Also in Protein design on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-28BioGeometrySeries A+ · not disclosed; the A series to date tops $100MBuilds generative models for biology: GeoFlow, an all-atom model that predicts the structures of proteins and their complexes and designs binders, and GeoCell, a virtual-cell model of how cells' gene expression responds to genetic and drug perturbations. An automated lab expresses and tests the designs and feeds the data back. It designs antibodies, vaccines, peptides and enzymes for partners and its own pipeline, including synthetic-biology products.
• 2026-09-24BigHat BiosciencesSeries C · $75MDesigns antibodies with machine learning tied to a fast automated wet lab (Milliner) that makes and tests designs; its lead drug BHB810 is in the clinic.
• 2026-08-11Aureka BiotechnologiesSeries B · $100MDesigns antibodies with its own biological foundation model, AuraIDE (released in open form as OpenDDE), trained and retrained on data from its own single-cell functional screens.
• 2026-07-14Chai DiscoverySeries C · $400MBuilds AI models that predict how molecules bind and design antibodies from scratch, and licenses them to drugmakers as software.
• 2026-03-20Helixon (Earendil Labs)Round (unnamed) · $787MAI protein modelling plus high-throughput experiments to design antibodies, especially bispecifics, which it licenses to Sanofi and Genentech and develops in-house.
• 2026-02-26Generate:BiomedicinesIPO · $400MA Flagship company using generative AI to design protein drugs such as antibodies, peptides and enzymes, and developing them itself.

All 15 in this field →